aiv infeqcia/SidsiT avadmyofTa mkurnaloba da movla (klinikuri ...
aiv infeqcia/SidsiT avadmyofTa mkurnaloba da movla (klinikuri ...
aiv infeqcia/SidsiT avadmyofTa mkurnaloba da movla (klinikuri ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
imunokompromitirebul <strong>aiv</strong> inficirebulebSi vaqvinaciis Semdgomi<br />
imunuri pasuxis <strong>da</strong>qveiTebis albaTobis gamo aucilebelia <strong>da</strong>cviTi<br />
RonisZiebebis mniSvnelobis xazgasma. busteruli rekomen<strong>da</strong>ciebi <strong>aiv</strong><br />
inficirebuli <strong>da</strong> imunokompetenturi pirebisaTvis erTnairia.<br />
4.9. tifis vaqcina (Vi polisaqaridi)<br />
<strong>da</strong>bali efeqturobisa <strong>da</strong> gverdiTi reaqciebis sixSiris gamo Zveli<br />
inaqtivirebuli vaqcina rekomendebuli ar aris, Tumca ekonomikur<br />
mizezTa gamo zogierT qveyanaSi is mainc iwarmoeba.<br />
parenteruli <strong>da</strong>xocili vaqcina, romelic Seicavs Vi polisaqarids<br />
kanqveS an kunTSi erTjeradi dozirebisas zomierad efeqturia (50-80%).<br />
vaqcina ineqcii<strong>da</strong>n 7 dReSi uzrunvelyofs proteqcias, romelic<br />
narCundeba sul mcire ori weli. riskis qveS myofi pirebisTvis<br />
rekomendebulia bustireba yovel sam weliwadSi.<br />
<strong>aiv</strong> inficirebul pirebs salmonelas StamiT inficirebis maRali riski<br />
aqvT. gar<strong>da</strong> amisa imunodeficiti ganapirobebs baqteriemias<br />
antibiotikebis mimarT rezistentobas, <strong>da</strong>avadebis relafss <strong>da</strong> persistul<br />
<strong>infeqcia</strong>s. miuxe<strong>da</strong>vad imisa, rom zoga<strong>da</strong>d saerTaSoriso mogzaurobisas<br />
20 FSME: pirveladi kursis saxiT gamoiyeneba 2 doza 14 dRis intervaliT, xolo mesame<br />
doza 9-12 Tvis Semdeg; Encepur: sami doza 0, 7 <strong>da</strong> 21 dReze pirveladi kursis saxiT,<br />
meoTxe doza 12-18 Tvis Semdeg.<br />
saWiro ar aris, Vi polisaqaridis Semcveli vaqcina rekomendebulia<br />
yvela <strong>aiv</strong> inficirebulisaTvis, romelic gegmavs mogzaurobas<br />
eqspoziciis maRali riskis arealSi. mosalodnel eqspoziciamde sul<br />
mcire ori kviriT adre un<strong>da</strong> Catardes erTjeradi vaqcinacia. tifis<br />
vaqcina ar uzrunvelyofs proteqcias 100%-Si <strong>da</strong> pasuxi SiZleba kidev<br />
ufro Semcirdes <strong>aiv</strong> <strong>infeqcia</strong>/<strong>SidsiT</strong> <strong>da</strong>avadebulebSi. zoga<strong>da</strong>d bustireba<br />
rekomendebulia yovel sam weliwadSi. maTTvis ki, romelTa CD4+<br />
ujredebis ricxvi 200/mm 3 -ze naklebia. es intervali SeiZleba Semcirdes<br />
or wlamde. mogzaurebs un<strong>da</strong> mieceT rekomen<strong>da</strong>ciebi sakvebTan <strong>da</strong><br />
sasmelTan <strong>da</strong>kavSirebuli akrZalvebis Sesaxeb.<br />
4.10. sxva <strong>da</strong>xocili antigenebi<br />
<strong>da</strong>xocili antigenebis Semcveli sxva vaqcinebi, rogoricaa iaponuri<br />
encefalitis, Savi Wirisa <strong>da</strong> jilexis vaqcinebi ar warmoadgens safrTxes<br />
<strong>aiv</strong> /<strong>SidsiT</strong> <strong>da</strong>avadebulTTavis, miuxe<strong>da</strong>vad maTi imunologiuri statusisa.<br />
es vaqcinebi gamoiyeneba iseve, rogorc ara <strong>aiv</strong> inficirebul pirebSi.<br />
4.1.1. imunoglobulinebis gamoyeneba<br />
4.11.1. B hepatitis imunoglobulini (HBIg)<br />
imunokompromitirebul pirebSi, maT Soris <strong>aiv</strong> <strong>infeqcia</strong>/<strong>SidsiT</strong><br />
<strong>da</strong>avadebulebSi, B hepatitis imunoglobulini gamoiyeneba igive<br />
125
Change language